Récepteur Trk
Les inhibiteurs des récepteurs Trk ciblent les kinases des récepteurs de la tropomyosine (Trk), une famille de récepteurs à activité tyrosine kinase qui jouent un rôle important dans le développement et la fonction du système nerveux. Les récepteurs Trk sont impliqués dans la signalisation des neurotrophines, essentielle à la survie, à la différenciation et à la croissance des neurones. La dérégulation de la signalisation Trk est associée à des troubles neurologiques et à certains cancers. Chez CymitQuimica, nous proposons des inhibiteurs de récepteurs Trk pour soutenir vos recherches en neurobiologie, oncologie et maladies neurodégénératives.
59 produits trouvés pour "Récepteur Trk"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
TrkA-IN-9
CAS :<p>TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.</p>Formule :C31H32N4O4Couleur et forme :SolidMasse moléculaire :524.61PF-06273340
CAS :<p>PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。</p>Formule :C23H22ClN7O3Degré de pureté :98% - 98.00%Couleur et forme :SolidMasse moléculaire :479.92NMS-P626
CAS :<p>NMS-P626 functions as an inhibitor targeting TRKA, TRKB, and TRKC, exhibiting IC 50 values of 8 nM, 7 nM, and 3 nM respectively. It effectively suppresses KM12 cell growth by inhibiting the phosphorylation of TPM3-TRKA and the subsequent downstream signaling, demonstrating an IC 50 of 19 nM specifically for KM12 cells. This compound is applicable in the study of colorectal cancer.</p>Formule :C28H35F2N7O4SCouleur et forme :SolidMasse moléculaire :603.68BNN-20
CAS :<p>BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.</p>Formule :C20H30O2Couleur et forme :SolidMasse moléculaire :302.45TrkC-IN-1
CAS :<p>TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.</p>Formule :C28H20BrN5O2Couleur et forme :SolidMasse moléculaire :538.395ONO-7579
CAS :<p>ONO-7579, an orally active TRKA inhibitor, effectively suppresses tumor growth by inhibiting TRKA phosphorylation. In KM12 colorectal cancer cells, it exhibits an EC 50 of 17.6 ng/g, indicating that a concentration of 17.6 ng per gram of tumor tissue reduces the activity of phosphorylated TRKA by 50%. This compound is utilized in cancer research.</p>Formule :C24H18ClF3N6O4SCouleur et forme :SolidMasse moléculaire :578.95HS-345
CAS :<p>HS-345, a TrkA/Akt inhibitor, exhibits potent anti-pancreatic cancer properties. This compound inhibits the growth and proliferation of pancreatic cancer cells by blocking the TrkA/Akt signaling pathway and induces cell apoptosis (Apoptosis). Additionally, HS-345 inhibits angiogenesis by reducing the expression of HIF-1α and VEGF. It holds promise for use in pancreatic cancer research.</p>Formule :C19H18N6O2SCouleur et forme :SolidMasse moléculaire :394.45Trk-IN-4
CAS :<p>Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.</p>Formule :C24H23F4N5O4Degré de pureté :98.13%Couleur et forme :SolidMasse moléculaire :521.46TrkB-IN-1
CAS :<p>TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.</p>Formule :C19H16N2O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :368.34
